IP Verse

Amgen Inc competitive analysis

Latest oppositions filed by Amgen Inc

Explore patent oppositions filed by Amgen Inc against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Mar 12, 2026
Patent NumberTitleApplicantOpposition Date
EP4252857
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSJun 23, 2025
EP3384049
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VegfREGENERON PHARMACEUTICALSApr 22, 2024
EP3536712
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSFeb 29, 2024
EP3716992
Use Of A Vegf Antagonist To Treat Angiogenic Eye DisordersREGENERON PHARMACEUTICALSMay 10, 2023
EP3230316
Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization LesionBAYER HEALTHCAREOct 5, 2022
EP2825558
Combination Therapy For The Treatment Of Ovarian CancerF HOFFMANN LA ROCHEFeb 17, 2020
EP2756004
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSDec 27, 2019
EP3038647
Combination Therapy For The Treatment Of GlioblastomaF HOFFMANN LA ROCHEDec 23, 2019

Latest patents of Amgen Inc opposed by its competitors

Explore Amgen Inc's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Mar 12, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3381942
Oct 1, 2025A Method For Treating Melanoma Using A Herpes Simplex Virus And An Immune Checkpoint Inhibitor1
EP3658203
Oct 1, 2025Drug Delivery Device With Gear Module And Related Method Of Assembly2
EP3661562
Oct 2, 2024Method Of Conjugation Of Cys-Mabs1
EP3570885
Sep 18, 2024Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)3
EP4209499
Aug 7, 2024Charged Depth Filtration Of Antigen-Binding Proteins7
EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents3
EP3926051
May 8, 2024Methods For Harvesting Mammalian Cell Cultures1
EP3151882
Apr 10, 2024Controllable Drug Delivery System And Method Of Use2
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3

Latest PTAB cases involving Amgen Inc

Discover the latest PTAB cases involving Amgen Inc, highlighting their recent legal challenges and patent disputes.

Last updated on: Mar 12, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Amgen Inc

IPR2025-00601Feb 28, 2025AMGENBRISTOL MYERS SQUIBBDiscretionary Denial
IPR2025-00602Feb 28, 2025AMGENBRISTOL MYERS SQUIBBDiscretionary Denial
IPR2025-00603Feb 28, 2025AMGENBRISTOL MYERS SQUIBBTerminated
IPR2023-00106Nov 2, 2022REPLIMUNEAMGENTerminated-Settled
IPR2021-00528Feb 10, 2021PFIZERAMGENTerminated-Settled
IPR2021-00326Dec 15, 2020LUPINAMGENInstitution Denied
IPR2020-00314Dec 20, 2019FRESENIUS KABI USAAMGENTerminated-Settled
IPR2019-01183Jun 8, 2019FRESENIUS KABI USAAMGENTerminated-Settled
IPR2019-00971Apr 14, 2019FRESENIUS KABI USAAMGENInstitution Denied
IPR2019-00791Mar 7, 2019KASHIV BIOSCIENCESAMGENTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Amgen Inc with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Mar 12, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AMGEN8138811
JAMES POOLE158 - - -
REGENERON PHARMACEUTICALS3894931
STRAWMAN351 - - -